Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis123

https://doi.org/10.3945/ajcn.112.040741Get rights and content
Under an Elsevier user license
open archive

ABSTRACT

Background:

Coenzyme Q10 (CoQ10; also called ubiquinone) is an antioxidant that has been postulated to improve functional status in congestive heart failure (CHF). Several randomized controlled trials have examined the effects of CoQ10 on CHF with inconclusive results.

Objective:

The objective of this meta-analysis was to evaluate the impact of CoQ10 supplementation on the ejection fraction (EF) and New York Heart Association (NYHA) functional classification in patients with CHF.

Design:

A systematic review of the literature was conducted by using databases including MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and manual examination of references from selected studies. Studies included were randomized controlled trials of CoQ10 supplementation that reported the EF or NYHA functional class as a primary outcome. Information on participant characteristics, trial design and duration, treatment, dose, control, EF, and NYHA classification were extracted by using a standardized protocol.

Results:

Supplementation with CoQ10 resulted in a pooled mean net change of 3.67% (95% CI: 1.60%, 5.74%) in the EF and −0.30 (95% CI: −0.66, 0.06) in the NYHA functional class. Subgroup analyses showed significant improvement in EF for crossover trials, trials with treatment duration ≤12 wk in length, studies published before 1994, and studies with a dose ≤100 mg CoQ10/d and in patients with less severe CHF. These subgroup analyses should be interpreted cautiously because of the small number of studies and patients included in each subgroup.

Conclusions:

Pooled analyses of available randomized controlled trials suggest that CoQ10 may improve the EF in patients with CHF. Additional well-designed studies that include more diverse populations are needed.

Cited by (0)

1

From the Department of Medicine, School of Medicine (ADF and LAB), and the Department of Epidemiology, School of Public Health and Tropical Medicine (AMT-P and LAB), Tulane University, New Orleans, LA.

2

Supported by a grant from the Research Enhancement Fund of Tulane University (AMT-P) and grant K08 HL091108 from the National Heart, Lung, and Blood Institute (LAB).

3

Address request reprints and correspondence to AD Fotino, Department of General Internal Medicine and Geriatrics, Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-16, New Orleans, LA 70112. E-mail: [email protected].

4

Abbreviations used: CHF, congestive heart failure; CoQ10, coenzyme Q10; EF, ejection fraction; NYHA, New York Heart Association.